Vaccine development for chronic myelogenous leukaemia

Lancet. 2005 Feb;365(9460):631-2. doi: 10.1016/S0140-6736(05)17957-4.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Benzamides
  • Cancer Vaccines / therapeutic use*
  • Fusion Proteins, bcr-abl / immunology*
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
  • Humans
  • Imatinib Mesylate
  • Immunotherapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Piperazines / administration & dosage
  • Pyrimidines / administration & dosage
  • Saponins / administration & dosage

Substances

  • Adjuvants, Immunologic
  • Antineoplastic Agents
  • Benzamides
  • Cancer Vaccines
  • Piperazines
  • Pyrimidines
  • Saponins
  • saponin QA-21V1
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl